Arbutus Biopharma マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Mike McElhaugh

最高経営責任者

US$1.6m

報酬総額

CEO給与比率	29.8%
CEO在任期間	2yrs
CEOの所有権	n/a
経営陣の平均在職期間	3.2yrs
取締役会の平均在任期間	6.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Arbutus Biopharma の収益と比較して、Mike McElhaugh の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$77m
Jun 30 2024	n/a	n/a	-US$77m
Mar 31 2024	n/a	n/a	-US$74m
Dec 31 2023	US$2m	US$483k	-US$73m
Sep 30 2023	n/a	n/a	-US$75m
Jun 30 2023	n/a	n/a	-US$73m
Mar 31 2023	n/a	n/a	-US$70m
Dec 31 2022	US$1m	US$449k	-US$69m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$76m
Mar 31 2022	n/a	n/a	-US$85m
Dec 31 2021	n/a	n/a	-US$88m
Sep 30 2021	n/a	n/a	-US$87m
Jun 30 2021	n/a	n/a	-US$84m
Mar 31 2021	n/a	n/a	-US$79m
Dec 31 2020	US$1m	US$415k	-US$76m

報酬と市場: Mikeの総報酬 ($USD 1.62M ) は、 UK市場 ($USD 1.46M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Mikeの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Mike McElhaugh (50 yo)

2yrs

在職期間

US$1,620,485

報酬

Mr. Michael J. McElhaugh, also known as Mike, co-founded Arbutus Biopharma Inc. in 2012 and serves as its Interim President and Chief Executive Officer and Director since January 1, 2024. Mr. McElhaugh had...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Michael McElhaugh	Co-Founder	2yrs	US$1.62m	データなし
Michael Sofia	Chief Scientific Officer	9.8yrs	US$1.61m	0.79% $ 5.2m
David Hastings	CFO & Chief Accounting Officer	6.4yrs	US$1.46m	0.0088% $ 58.7k
Lisa Caperelli	Vice President of Investor Relations	3.2yrs	データなし	データなし
J. Naftzger	General Counsel	1.3yrs	データなし	データなし
Shannon Briscoe	Vice President of Human Resources	no data	データなし	データなし
Karen Sims	Chief Medical Officer	1.3yrs	データなし	0.0028% $ 18.5k
R. Mackay-Dunn	Corporate Secretary	14.5yrs	データなし	データなし

3.2yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: 0SGCの経営陣は経験豊富であると考えられます ( 3.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Michael McElhaugh	Co-Founder	less than a year	US$1.62m	データなし
Richard Henriques	Independent Non-Executive Director	9.9yrs	US$174.24k	0.00053% $ 3.5k
Daniel Burgess	Independent Director	7.7yrs	US$161.74k	0% $ 0
Keith Manchester	Independent Non-Executive Director	9.7yrs	US$156.74k	0.024% $ 161.7k
Adrian Di Bisceglie	Member of Scientific Advisory Board	no data	データなし	データなし
Charles Rice	Member of Scientific Advisory Board	no data	データなし	データなし
James Meyers	Independent Director	6.1yrs	US$176.74k	0% $ 0
William Symonds	Chairman of Scientific Advisory Board	6.1yrs	データなし	データなし
Frank Torti	Independent Chairman of the Board of Directors	6yrs	US$187.99k	0% $ 0
Fabien Zoulim	Member of Scientific Advisory Board	no data	データなし	データなし
Scott Biller	Member of Scientific Advisory Board	no data	データなし	データなし
Ulrike Protzer	Member of Scientific Advisory Board	no data	データなし	データなし

6.1yrs

平均在職期間

57.5yo

平均年齢

経験豊富なボード: 0SGCの取締役会は経験豊富であると考えられます ( 6.1年の平均在任期間)。

Arbutus Biopharma マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024

Arbutus Biopharma Corporation, Annual General Meeting, May 22, 2024

Arbutus Biopharma Corporation Announces CEO Changes

Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors

Arbutus Biopharma Corporation Appoints Two New Executives

Arbutus Biopharma Corporation Appoints Two New Executives

Recent updates

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.12 loss in 3Q 2023)

Arbutus Biopharma Corporation to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.10 loss in 2Q 2023)

Arbutus Biopharma Corporation to Report Q2, 2024 Results on Aug 01, 2024

Arbutus Biopharma Corporation Announces New Preliminary End-Of- Treatment Data from the Phase 2A Clinical Trial

Arbutus Biopharma Corporation Announces New Data from its Phase 2a Clinical Trial IM-PROVE I (AB-729-201)

Whitefort Capital Management Sends an Open Letter to Shareholders of Arbutus Biopharma

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders

Whitefort Capital Management Engages with Arbutus Biopharma

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.10 loss in 1Q 2023)

Arbutus Biopharma Corporation Announces Retirement of Chief Scientific Officer, Michael J. Sofia Effective December 31, 2024

Arbutus Biopharma Corporation to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Corporation, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: US$0.44 loss per share (vs US$0.46 loss in FY 2022)

Arbutus Biopharma Corporation to Report Q4, 2023 Results on Feb 29, 2024

Arbutus Biopharma, Inc. Announces Clinical Development Milestones to Advance Its HBV Pipeline

Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD

Arbutus Biopharma Corporation Announces CEO Changes

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.12 loss in 3Q 2022)

Arbutus Biopharma Corporation to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Share price stability

Arbutus Biopharma Corporation Announces Pipeline Updates and Dosing of First Subject in Phase 1a/1b Clinical Trial with AB-101

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.095 loss in 2Q 2022)

Arbutus Biopharma Corporation to Report Q2, 2023 Results on Aug 03, 2023

Arbutus Biopharma Corporation Announces the Appointment of Melissa V. Rewolinski to Its Board of Directors

Arbutus Biopharma Corporation Appoints Two New Executives

Arbutus Biopharma Corporation Appoints Two New Executives

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2A Triple Combination Clinical Trial That Includes A Pd-1 Monoclonal Antibody

Arbutus Biopharma Corporation to Present AB-729 and AB-836 Data at EASL Congress 2023

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.11 loss in 1Q 2022)

Full year 2022 earnings released: US$0.46 loss per share (vs US$0.83 loss in FY 2021)

Arbutus Biopharma Corporation Announces Resignation of Tram Tran from the Board of Directors, Effective on February 26, 2023

Arbutus Biopharma Corporation to Report Q4, 2022 Results on Mar 02, 2023

Arbutus Biopharma Corporation Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Insufficient new directors

Arbutus Biopharma Corporation Appoints Mike Mcelhaugh as Chief Operating Officer, Effective as of November 1, 2022

Arbutus Biopharma Corporation Announces Resignation of Gaston Picchio as Chief Development Officer

Arbutus Biopharma Corporation to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.095 loss per share (vs US$0.23 loss in 2Q 2021)

Arbutus Biopharma Corporation to Report Q2, 2022 Results on Aug 04, 2022

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with Ab-729 and Capsid Inhibitor

Arbutus Biopharma Corporation Presents New Data on AB-729, Ab-836 and AB-101 At the EASL International Liver Congress™ 2022 and Provides Ab-836 Clinical Update

Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Insufficient new directors

First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2021)

Arbutus Biopharma Corporation to Report Q1, 2022 Results on May 05, 2022

Arbutus Biopharma Corporation, Annual General Meeting, May 25, 2022

Arbutus Provides Pipeline Updates

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Arbutus Biopharma Corporation to Report Q4, 2021 Results on Mar 03, 2022

Antios Therapeutics and Arbutus Biopharma Announces First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

Arbutus Biopharma Corporation announced that it expects to receive $14.999999 million in funding from Qilu Pharmaceutical Co., Ltd.

Arbutus Biopharma Corporation Announces Preliminary Data from its On-Going Phase 1A/1B Clinical Trial Demonstrating That its Next Generation Capsid Inhibitor, AB-836

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.27 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.23 loss per share (vs US$0.24 loss in 2Q 2020)

Arbutus Biopharma Corporation Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

First quarter 2021 earnings released: US$0.21 loss per share (vs US$0.25 loss in 1Q 2020)

Arbutus Biopharma Corporation Receives Regulatory Approval to Initiate Phase 1a/1b Clinical Trial with AB-836, its Proprietary Oral Capsid Inhibitor for the Treatment of HBV Infection

Arbutus Biopharma Corporation, Annual General Meeting, May 26, 2021

Full year 2020 earnings released: US$1.00 loss per share (vs US$2.89 loss in FY 2019)

Revenue beats expectations

Assembly Biosciences, Inc. and Arbutus Biopharma Corporation Announce Initiation of Phase 2 Clinical Trial of Assembly Bio's Investigational Hepatitis B Virus Core Inhibitor Candidate

Arbutus Biopharma Corporation to Report Q4, 2020 Results on Mar 04, 2021

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /34